NASDAQ:ZVRA

Zevra Therapeutics (ZVRA) Stock Forecast, Price & News

$5.40

-0.03 (-0.55%)

(As of 09:02 AM ET)

Compare

Today's Range: $5.40
▼
$5.40
50-Day Range: $4.23
▼
$6.29
52-Week Range: $4.03
▼
$6.92

Volume: 7,730 shs
Average Volume: 231,863 shs
Market Capitalization: $186.52 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $12.00

Zevra Therapeutics MarketRank™ Forecast

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 121.0% Upside
$12.00 Price Target
Short Interest: Bearish
6.39% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.06
Based on 2 Articles This Week
Insider Trading: Acquiring Shares
$178,055 Bought Last Quarter
Proj. Earnings Growth: Growing
From ($1.47) to ($0.79) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.79 out of 5 stars

Medical Sector

727th out of 982 stocks

Pharmaceutical Preparations Industry

354th out of 474 stocks

3.5

Analyst's Opinion

Consensus Rating
Zevra Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $12.00, Zevra Therapeutics has a forecasted upside of 121.0% from its current price of $5.43.
Amount of Analyst Coverage
Zevra Therapeutics has only been the subject of 1 research reports in the past 90 days.

1.0

Short Interest

Percentage of Shares Shorted
6.39% of the float of Zevra Therapeutics has been sold short.
Short Interest Ratio / Days to Cover
Zevra Therapeutics has a short interest ratio ("days to cover") of 7.7.
Change versus previous month

0.0

Dividend Strength

Dividend Yield
Zevra Therapeutics does not currently pay a dividend.
Dividend Growth
Zevra Therapeutics does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for ZVRA.

1.7

News and Social Media Coverage

News Sentiment
Zevra Therapeutics has a news sentiment score of 0.06. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.52 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 2 news articles for Zevra Therapeutics this week, compared to 3 articles on an average week.
Search Interest
8 people have searched for ZVRA on MarketBeat in the last 30 days. This is an increase of 167% compared to the previous 30 days.
MarketBeat Follows
Only 2 people have added Zevra Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

1.7

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Zevra Therapeutics insiders have bought more of their company's stock than they have sold. Specifically, they have bought $178,055.00 in company stock and sold $0.00 in company stock.
Percentage Held by Insiders
Only 1.10% of the stock of Zevra Therapeutics is held by insiders.
Percentage Held by Institutions
Only 19.39% of the stock of Zevra Therapeutics is held by institutions.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Zevra Therapeutics are expected to grow in the coming year, from ($1.47) to ($0.79) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Zevra Therapeutics is -3.64, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Zevra Therapeutics is -3.64, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Zevra Therapeutics has a P/B Ratio of 2.18. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Zevra Therapeutics (NASDAQ:ZVRA) Stock

Zevra Therapeutics, Inc. is a clinical-stage specialty pharmaceutical company, which engages in the discovery and development of proprietary prodrugs. It focuses on the treatment of serious medical conditions such as attention deficit hyperactivity disorder, pain, and other central nervous system disorders through its platform technology known as Ligand Activated Therapy. The company was founded by Christal M. M. Mickle and Travis C. Mickle on October 30, 2006 and is headquartered in Celebration, FL.

Receive ZVRA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Zevra Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

ZVRA Stock News Headlines

June 3, 2023 | finance.yahoo.com

Zevra Therapeutics Presents Design of Phase 2 Clinical Trial Investigating KP1077 for the Treatment of Idiopathic Hypersomnia (IH) at Beyond Sleepy 2023

May 21, 2023 | americanbankingnews.com

Insider Buying: Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Director Buys 10,000 Shares of Stock

June 7, 2023 | Edge On The Street (Ad)

The $193 Billion US-China War You Don't Know About

They're fighting for control of lithium – a key ingredient in EVs and clean energy technology. It's arguably the most important commodity of the 21st century. China owns 80% of global supply. But the US plans to grab a massive slice of the lithium market, which is forecasted to quadruple to $193 billion by 2028, according to Fortune Business Insights.

May 20, 2023 | americanbankingnews.com

R. Laduane Clifton Purchases 2,740 Shares of Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Stock

May 17, 2023 | americanbankingnews.com

Zevra Therapeutics (NASDAQ:ZVRA) Releases Earnings Results, Misses Expectations By $0.08 EPS

May 16, 2023 | finance.yahoo.com

Q1 2023 Zevra Therapeutics Inc Earnings Call

May 15, 2023 | washingtonpost.com

Zevra Therapeutics: Q1 Earnings Snapshot

May 15, 2023 | finance.yahoo.com

Zevra Therapeutics (ZVRA) Reports Q1 Loss, Tops Revenue Estimates

June 7, 2023 | Edge On The Street (Ad)

The $193 Billion US-China War You Don't Know About

May 15, 2023 | finance.yahoo.com

Zevra Therapeutics Reports Corporate Updates and First Quarter 2023 Financial Results

May 12, 2023 | msn.com

A Preview Of Zevra Therapeutics's Earnings

May 10, 2023 | finance.yahoo.com

Zevra Therapeutics will Participate in RBC Capital Markets Global Healthcare Conference on May 16, 2023

May 9, 2023 | finance.yahoo.com

Zevra Therapeutics to Report First Quarter 2023 Results on May 15, 2023

May 8, 2023 | msn.com

Zevra Therapeutics CEO resigns, Tamara Favorito appointed as Chair of the Board

May 8, 2023 | finance.yahoo.com

Zevra Announces Board of Directors and Leadership Changes

May 4, 2023 | markets.businessinsider.com

Analysts Offer Insights on Healthcare Companies: Zevra Therapeutics (ZVRA) and Morphosys Ag (MOR)

May 3, 2023 | finance.yahoo.com

Zevra Therapeutics Announces FDA Acceptance of IND Application for KP1077 in Narcolepsy

April 21, 2023 | americanbankingnews.com

Head-To-Head Review: Zevra Therapeutics (NASDAQ:ZVRA) and ERBA Diagnostics (OTCMKTS:ERBA)

April 18, 2023 | seekingalpha.com

ZVRA Zevra Therapeutics, Inc.

April 17, 2023 | benzinga.com

Leading Proxy Advisory Firms ISS and Glass Lewis Demonstrate Strong Support for Zevra's Transformation Strategy

April 17, 2023 | finance.yahoo.com

Leading Proxy Advisory Firms ISS and Glass Lewis Demonstrate Strong Support for Zevra’s Transformation Strategy

April 17, 2023 | finance.yahoo.com

Why Investors Shouldn't Be Surprised By Zevra Therapeutics, Inc.'s (NASDAQ:ZVRA) 31% Share Price Surge

April 11, 2023 | americanbankingnews.com

Zevra Therapeutics (ZVRA) versus Its Peers Head-To-Head Comparison

April 6, 2023 | investing.com

Zevra Therapeutics Inc (ZVRA)

April 4, 2023 | finance.yahoo.com

Zevra Therapeutics Announces Submission of IND for KP1077 in Narcolepsy

April 3, 2023 | americanbankingnews.com

Zevra Therapeutics (ZVRA) & Its Peers Head-To-Head Survey

March 30, 2023 | thestreet.com

Zevra Therapeutics Inc.

See More Headlines

ZVRA Price History

30 days | 90 days | 365 days | Advanced Chart

ZVRA Company Calendar

Last Earnings: 5/15/2023
Today: 6/07/2023
Next Earnings (Estimated): 8/10/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:ZVRA
CUSIP: N/A
CIK: 1434647
Web: www.kempharm.com
Phone: (321) 939-3416
Fax: 319-665-2577
Employees: N/A
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $12.00
High Stock Price Forecast: $12.00
Low Stock Price Forecast: $12.00
Forecasted Upside/Downside: +121.0%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 1 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($1.49)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-41,540,000.00
Net Margins: -548.93%
Pretax Margin: -558.38%
Return on Equity: -38.58%
Return on Assets: -29.00%

Debt

Debt-to-Equity Ratio: 0.18
Current Ratio: 6.68
Quick Ratio: 6.68

Sales & Book Value

Annual Sales: $10.46 million
Price / Sales: 17.93
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $2.49 per share
Price / Book: 2.18

Miscellaneous

Outstanding Shares: 34,540,000
Free Float: 34,160,000
Market Cap: $187.55 million
Optionable: Optionable
Beta: 2.19

Key Executives

Richard W. Pascoe
Chief Executive Officer & Director

R. LaDuane Clifton
Chief Financial Officer, Secretary & Treasurer

Sven Guenther
Chief Scientific Officer

Daniel Gallo
Senior Vice President-Medical Affairs & Advocacy

Timothy J. Sangiovanni
Vice President & Controller

Key Competitors

View All Competitors

Insiders

View All Insider Transactions

ZVRA Stock - Frequently Asked Questions

Should I buy or sell Zevra Therapeutics stock right now?: 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Zevra Therapeutics in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" ZVRA shares.
View ZVRA analyst ratings or view top-rated stocks.
What is Zevra Therapeutics' stock price forecast for 2023?: 1 Wall Street research analysts have issued twelve-month target prices for Zevra Therapeutics' stock. Their ZVRA share price forecasts range from $12.00 to $12.00. On average, they anticipate the company's share price to reach $12.00 in the next twelve months. This suggests a possible upside of 121.0% from the stock's current price.
View analysts price targets for ZVRA or view top-rated stocks among Wall Street analysts.
How have ZVRA shares performed in 2023?: Zevra Therapeutics' stock was trading at $5.39 at the start of the year. Since then, ZVRA shares have increased by 0.7% and is now trading at $5.43.
View the best growth stocks for 2023 here.
When is Zevra Therapeutics' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, August 10th 2023.
View our ZVRA earnings forecast.
How were Zevra Therapeutics' earnings last quarter?: Zevra Therapeutics, Inc. (NASDAQ:ZVRA) issued its quarterly earnings data on Monday, May, 15th. The company reported ($0.34) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.26) by $0.08. The business had revenue of $2.88 million for the quarter, compared to analysts' expectations of $2.77 million. Zevra Therapeutics had a negative trailing twelve-month return on equity of 38.58% and a negative net margin of 548.93%.

What ETF holds Zevra Therapeutics' stock ?: iShares Neuroscience and Healthcare ETF holds 3,689 shares of ZVRA stock, representing 0.43% of its portfolio.
What is Zevra Therapeutics' stock symbol?: Zevra Therapeutics trades on the NASDAQ under the ticker symbol "ZVRA."
How do I buy shares of Zevra Therapeutics?: Shares of ZVRA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Zevra Therapeutics' stock price today?: One share of ZVRA stock can currently be purchased for approximately $5.43.
How much money does Zevra Therapeutics make?: Zevra Therapeutics (NASDAQ:ZVRA) has a market capitalization of $187.55 million and generates $10.46 million in revenue each year. The company earns $-41,540,000.00 in net income (profit) each year or ($1.49) on an earnings per share basis.
How can I contact Zevra Therapeutics?: Zevra Therapeutics' mailing address is 1180 Celebration Boulevard Suite 103, Celebration FL, 34747. The official website for the company is www.kempharm.com. The company can be reached via phone at (321) 939-3416, via email at jrando@tiberend.com, or via fax at 319-665-2577.

This page (NASDAQ:ZVRA) was last updated on 6/7/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial